Pain Channel
Topics & Medications
Related Channels

Rybix ODT

If you are an adult with moderate-to-moderately severe pain, your healthcare provider may recommend Rybix ODT. This medication dissolves rapidly on the tongue, which means it doesn't need to be taken with water. It is generally taken between two and four times a day. Most people tolerate it well; however, side effects (such as nausea and constipation) are possible.

What Is Rybix ODT?

This medication is no longer available, as it has been discontinued by the manufacturer. Other tramadol products are still available. 
Rybix™ ODT (orally disintegrating tramadol) is a prescription pain medication approved for treating moderate-to-moderately severe pain in adults. It comes in the form of a tablet that dissolves rapidly on the tongue, without any need for water.
(Click Rybix ODT Uses for more information on this topic, including possible off-label uses.)

Who Makes Rybix ODT?

Rybix ODT is made by Ethypharm S.A. for Victory Pharma, Inc.

Abuse Potential

Rybix ODT has a significant potential for both psychological and physical dependence and abuse, similar to morphine. Initially, tramadol (the active ingredient in Rybix ODT) was marketed as a pain medication with very little potential for abuse.
However, healthcare providers quickly recognized that many of their patients had become addicted to tramadol. Now, the prescribing information for tramadol medications (including Rybix ODT) contains numerous different warnings about the potential for abuse.
For more information, visit the following eMedTV articles:
The Top 17 Side Effects of Chemotherapy

Rybix ODT Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.